Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.37 |
| ▸ | HTR2B | P41595 | 10/20 | 0.37 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634074 | 1.00 | HTR2C (0.37) | HTR2CHTR2BHTR2ASCN4ASCN9A | |
| SCHEMBL5631361 | 1.00 | HTR2C (0.37) | HTR2CHTR2BHTR2ASCN4ASCN9A | |
| Trifluoroacetic Acid SCHEMBL5630462 | 0.93 | ALDH1A1 (0.37) | HTR2CHTR2BHTR2ALIPEALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5732644 | 0.93 | ALDH1A1 (0.37) | HTR2CHTR2BHTR2ALIPEALDH1A1 | |
| SCHEMBL5631132 | 0.91 | HTR2C (0.35) | HTR2CHTR2BHTR2ASCN4ASCN9A | |
| SCHEMBL5632634 | 0.82 | HTR2C (0.45) | HTR2CHTR2BHTR2AALDH1A1GAA | |
| SCHEMBL5632202 | 0.82 | HTR2C (0.45) | HTR2CHTR2BHTR2AALDH1A1GAA | |
| SCHEMBL5632208 | 0.82 | HTR2C (0.45) | HTR2CHTR2BHTR2AALDH1A1GAA | |
| SCHEMBL4434035 | 0.76 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6 | |
| Trifluoroacetic Acid SCHEMBL5732284 | 0.76 | HTR2C (0.42) | HTR2CHTR2BHTR2ASCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.